News Sentiment

XLO sentiment intelligence

Xilio Development Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 44 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 9.10 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

80/100 classification confidence.

Company focus 35

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-0.5% over one week, +9.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Market Reaction

Balanced read

54/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 80/100 classification
One-week reaction -0.5% Price digesting
Trend fit Trend inactive 9.5% over four weeks
Fair value -33.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 30
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 35
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
Stock Titan 9
TradingView 8
www.marketscreener.com 3
The Globe and Mail 2
dars.gov.et 2
TradingKey 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 24
Earnings 15
Analyst action 2
Regulatory and legal 1
Deals and strategy 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 44
Market source Direct company coverage

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xilio Therapeutics, Inc. announced the grant of non-qualified stock options to purchase 107,060 shares of its common stock to three new employees. These grants were made under the company's 2022 Inducement Stock Incentive Plan, with an exercise price of $9.22 per share, matching

Tone
Positive 59/100
Event
Market update
Published
09 Jul 2026 12:42
Source
Market source
TradingView Direct company coverage

Enterprise value to EBIT forward of Xilio Therapeutics, Inc. – NASDAQ:XLO

This article focuses on the enterprise value to EBIT forward for Xilio Therapeutics, Inc. (NASDAQ: XLO). It appears to be a financial data point provided by TradingView, indicating a specific valuation metric for the company. The content primarily consists of navigational and bra

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 02:11
Source
TradingView
Stock Titan Direct company coverage

Xilio lures three new employees with 107,060 stock options

Xilio Therapeutics (Nasdaq: XLO) has granted non-qualified stock options for 107,060 shares to three new employees, effective July 1, 2026. These options, with an exercise price of $9.22 per share and a ten-year term, serve as an inducement under Nasdaq Listing Rule 5635(c)(4). T

Tone
Positive 63/100
Event
Market update
Published
06 Jul 2026 20:09
Source
Stock Titan
Investing.com South Africa Direct company coverage

Xilio Therapeutics appoints Ben Harshbarger as chief legal officer By Investing.com

Xilio Therapeutics has appointed Ben Harshbarger as its new chief legal officer, leveraging his over two decades of legal and executive experience in the biopharmaceutical industry. Harshbarger previously served as chief legal officer at Astria Therapeutics and held leadership ro

Tone
Positive 66/100
Event
Market update
Published
30 Jun 2026 08:09
Source
Investing.com South Africa
TradingView Direct company coverage

Price to sales forward of Xilio Therapeutics, Inc. – NASDAQ:XLO

This article focuses on the "Price to sales forward" financial metric for Xilio Therapeutics, Inc. (NASDAQ: XLO). It appears to be a financial data point from TradingView, indicating a specific valuation ratio for the company over a defined period. The content primarily lists nav

Tone
Neutral 50/100
Event
Regulatory and legal
Published
29 Jun 2026 19:10
Source
TradingView
www.marketscreener.com Direct company coverage

Xilio Therapeutics, Inc.(NasdaqCM:XLO) added to Russell Microcap Value Benchmark Index

Xilio Therapeutics, Inc. (NasdaqCM:XLO) has been added to the Russell Microcap Value Benchmark Index, as announced on June 29, 2026. This move highlights the company's position within the microcap market and its valuation metrics. Xilio Therapeutics operates as a clinical-stage b

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 16:11
Source
www.marketscreener.com
TradingView Direct company coverage

Enterprise value to EBITDA forward of Xilio Therapeutics, Inc. – BOATS:XLO

This article provides financial information for Xilio Therapeutics, Inc. (XLO), specifically its enterprise value to EBITDA forward metric. The content highlights a specific financial indicator for the company, accessible through the Blue Ocean Alternative Trade System (BOATS) vi

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 14:11
Source
TradingView
www.marketscreener.com Direct company coverage

Xilio Therapeutics, Inc. Announces Appointment of Ben Harshbarger as Chief Legal Officer

Xilio Therapeutics, Inc. has announced the appointment of Ben Harshbarger as its new Chief Legal Officer. Harshbarger brings over two decades of legal and executive leadership experience in the biopharmaceutical industry, having previously served as Chief Legal Officer at Astria

Tone
Positive 70/100
Event
Market update
Published
29 Jun 2026 12:11
Source
www.marketscreener.com
Quiver Quantitative Direct company coverage

Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

Xilio Therapeutics has appointed Ben Harshbarger as its new chief legal officer, leveraging his extensive legal and strategic experience in the biotechnology sector. Harshbarger's role will be crucial in advancing Xilio's pipeline of immuno-oncology therapies, including the bispe

Tone
Positive 64/100
Event
Market update
Published
29 Jun 2026 11:41
Source
Quiver Quantitative
Stock Titan Direct company coverage

Xilio Therapeutics taps biotech veteran Ben Harshbarger as legal chief

Xilio Therapeutics has appointed Ben Harshbarger as its new chief legal officer, bringing over 20 years of biopharmaceutical legal and executive experience to the company. Harshbarger previously served at Astria Therapeutics, Novelion Therapeutics, Aegerion, Cubist, ViaCell, and

Tone
Positive 65/100
Event
Market update
Published
29 Jun 2026 11:11
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to revenue forward of Xilio Therapeutics, Inc. – BOATS:XLO

The article focuses on the enterprise value to revenue forward metric for Xilio Therapeutics, Inc. (XLO). It appears to be a financial data presentation or analysis page from TradingView, specifically looking at Xilio Therapeutics' financials within the pharmaceutical sector. The

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 03:41
Source
TradingView
www.marketscreener.com Direct company coverage

Xilio Therapeutics, Inc.(NasdaqCM: XLO) added to Russell Microcap Index

Xilio Therapeutics, Inc. (NasdaqCM: XLO) has been added to the Russell Microcap Index. The clinical-stage biotechnology company focuses on developing masked immuno-oncology therapies to treat cancer with reduced systemic side effects. Xilio Therapeutics also reported its first-qu

Tone
Positive 68/100
Event
Market update
Published
29 Jun 2026 01:50
Source
www.marketscreener.com
TradingView Direct company coverage

XLO Forecast — Price Target — Prediction for 2027

This article provides a detailed forecast and price target for Xilio Therapeutics, Inc. (XLO) stock, based on analyst opinions. It covers current stock performance, historical highs and lows, volatility metrics, market capitalization, and financial data including earnings, revenu

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 06:40
Source
TradingView
TradingView Direct company coverage

Xilio Therapeutics Inc Actuals & Estimates (NASDAQ:XLO)

This article provides an overview of Xilio Therapeutics Inc. (NASDAQ: XLO), including its current stock price, historical performance, analyst forecasts, and financial data. It covers earnings per share, revenue, market capitalization, and volatility, along with information on fu

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 02:10
Source
TradingView
TradingKey Direct company coverage

Xilio Therapeutics Inc (XLO) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides a historical overview of dividends and stock splits for Xilio Therapeutics Inc (XLO). It indicates that the company has not distributed any dividends in the past five years. However, it notes a 14-to-1 merger-related stock split effective March 12, 2026.

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Jun 2026 10:09
Source
TradingKey
TradingKey Direct company coverage

Xilio Therapeutics Inc (XLO) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Xilio Therapeutics Inc (XLO), highlighting its perfect earnings forecast score of 10.00 and a 'Strong Buy' analyst rating from one analyst. It details the average price target of $2.00, along with expected revenue and EPS for upcomin

Tone
Positive 70/100
Event
Earnings
Published
17 Jun 2026 01:40
Source
TradingKey
The Globe and Mail Direct company coverage

Xilio Therapeutics Adjusts Board Structure Following Shareholder Votes

Xilio Therapeutics has modified its board structure following its annual meeting by rebalancing its classified board and reappointing Daniel Curran as a Class III director. Shareholders also elected four Class II directors, ratified Ernst & Young LLP as the auditor, and approved

Tone
Neutral 50/100
Event
Market update
Published
14 Jun 2026 02:39
Source
The Globe and Mail
Stock Titan Direct company coverage

Xilio (XLO) director receives grant of 5,000 stock options at $7.99

Xilio Therapeutics director Shannon James Samuel was granted 5,000 stock options at an exercise price of $7.99 per share. These options will vest 100% on the earlier of June 11, 2027, or the company’s next annual stockholder meeting, contingent on his continued service. Following

Tone
Neutral 50/100
Event
Market update
Published
13 Jun 2026 13:09
Source
Stock Titan
Stock Titan Direct company coverage

Xilio Therapeutics (XLO) director receives grant of 5,000 stock options at $7.99

Xilio Therapeutics director Daniel J. Curran was granted 5,000 stock options at an exercise price of $7.99 per share. These options will vest 100% on the earlier of June 11, 2027, or the company's next annual meeting, contingent on his continued service. This transaction is a com

Tone
Neutral 50/100
Event
Market update
Published
13 Jun 2026 12:10
Source
Stock Titan
TradingView Direct company coverage

Daniel Curran reappointed to Class III director at Xilio

Xilio Therapeutics has reappointed Daniel Curran as a Class III director after he resigned as a Class II director to rebalance the board. This change, effective June 10, 2026, aims to achieve an equal balance of director membership across the three classes of the Board. The infor

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 20:39
Source
TradingView
Stock Titan Direct company coverage

Board changes and stock plan vote at Xilio Therapeutics (NASDAQ: XLO)

Xilio Therapeutics (NASDAQ: XLO) reported governance and compensation updates from its 2026 annual stockholder meeting. The company rebalanced its staggered board, moving Daniel Curran, M.D. from a Class II to a Class III director position without changing his compensation. Stock

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 19:39
Source
Stock Titan
Stock Titan Direct company coverage

Xilio Therapeutics (XLO) director Xu Yuan receives grant of 5,000 stock options

Xilio Therapeutics director Xu Yuan was granted 5,000 stock options as equity compensation, with an exercise price of $7.99 per share and an expiration date of June 10, 2036. The options, granted on June 11, 2026, will fully vest on the earlier of June 11, 2027, or the company's

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 19:39
Source
Stock Titan
Stock Titan Direct company coverage

Xilio Therapeutics (XLO) director granted options for 5,000 shares at $7.99

Xilio Therapeutics director Aoife Brennan was granted options for 5,000 shares of common stock at an exercise price of $7.99 per share. The options expire on June 10, 2036, and will vest 100% on the earlier of June 11, 2027, or the next annual stockholder meeting, contingent on h

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 19:39
Source
Stock Titan